Neurosteroid antidepressants on horizon

More than 14 million Americans suffer from clinical depression, yet one in three doesn’t experience relief from approved antidepressant drugs. A new treatment approach involving drugs called neurosteroids is on the horizon, however. Neurosteroids occur

Global phase 3 trial of zoliflodacin

The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organisation developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development